

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Glover Stephen C.</u> (Last) (First) (Middle) C/O ZYVERSA THERAPEUTICS, INC. 2200 N. COMMERCE PARKWAY, SUITE 208 (Street) WESTON FL 26333 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ZyVersa Therapeutics, Inc. [ZVSA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Executive Officer
	3. Date of Earliest Transaction (Month/Day/Year) 12/12/2022	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/12/2022		A		448,909	A	(1)	448,909	D	
Common Stock	12/12/2022		A		85,442	A	(1)	85,442	I	See footnote ⁽²⁾
Common Stock	12/12/2022		A		49,636	A	(1)	49,636	I	See footnote ⁽³⁾
Common Stock	12/12/2022		A		43,847	A	(1)	43,847	I	See footnote ⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Convertible Preferred Stock	\$10	12/12/2022		A		18		12/12/2022	(5)	Common Stock	1,750	(12)	1,750	D	
Stock Options (right to buy)	\$5.03	12/12/2022		A		138,980		(6)	04/11/2024	Common Stock	138,980	\$0	138,980	D	
Stock Options (right to buy)	\$5.03	12/12/2022		A		168,761		(7)	10/28/2026	Common Stock	168,761	\$0	168,761	D	
Stock Options (right to buy)	\$11.58	12/12/2022		A		264,838		(8)	04/02/2029	Common Stock	264,838	\$0	264,838	D	
Stock Options (right to buy)	\$16.36	12/12/2022		A		126,138		(9)	02/08/2031	Common Stock	126,138	\$0	126,138	D	
Stock Options (right to buy)	\$16.36	12/12/2022		A		79,417		(10)	02/03/2032	Common Stock	79,147	\$0	79,417	D	
Warrant (right to buy)	\$6.9	12/12/2022		A		70,881		(11)	12/12/2027	Common Stock	70,881	\$0	70,881	D	
Warrant (right to buy)	\$11.58	12/12/2022		A		3,022		(11)	10/31/2023	Common Stock	3,022	\$0	3,022	D	
Warrant (right to buy)	\$11.58	12/12/2022		A		17,903		(11)	10/31/2023	Common Stock	17,903	\$0	17,903	I	See footnote ⁽²⁾
Warrant (right to buy)	\$11.5	12/12/2022		A		1,750		(11)	12/12/2027	Common Stock	1,750	(12)	1,750	D	

Explanation of Responses:

1. Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement,

dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old ZyVersa as the surviving company of the Acquisition Merger and, after giving effect to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.

2. The securities are held of record by Asclepius Life Sciences Fund, L.P. ("ALS Fund"). Reporting Person serves as the managing member of ALS Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

3. The securities are held of record by Asclepius Master Fund, LTD. ("AM Fund"). Reporting Person serves as the managing director of AM Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

4. The securities are held of record by MedicaRx Inc. ("MRx"). Reporting Person serves as the managing director of MRx. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

5. The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.

6. 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015.

7. 100% of the option is immediately exercisable. The option vested on October 28, 2016.

8. 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020.

9. The option vests in 3 equal annual installments commencing on February 8, 2022.

10. The option vests in 3 equal annual installments commencing on January 28, 2023.

11. The warrant is immediately exercisable in full.

12. The Reporting Person paid \$1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of \$17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5.

/s/ Peter Wolfe, attorney-in-fact 12/14/2022
for Stephen C. Glover

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.